Apellis Pharmaceuticals Inc. APLS
$3.53
▼ -0.54% 24H
About
Apellis Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic compounds that inhibit the complement system to treat autoimmune and inflammatory diseases. Its key products include EMPAVELI, approved for paroxysmal nocturnal hemogl…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees733
TickerAPLS
Statistics
Market Cap$451.6M
Revenue (TTM)$95.0M
Net Income—
Net Margin—
EPS—
P/E38.35
P/S4.75
P/B12.65
EV/EBITDA31.94
ROE46.0%
Dividend Yield—
Price$3.53
Data: Twelve Data · Revenue = mcap / P/S